Literature DB >> 9843454

Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle.

B J Maron1, R A Nishimura, G K Danielson.   

Abstract

BACKGROUND: Ventricular septal myotomy/myectomy (Morrow procedure) is the standard surgical option for severely symptomatic patients with hypertrophic cardiomyopathy (HCM) and marked basal obstruction to left ventricular outflow due to mitral valve systolic anterior motion. In some patients, however, congenital malformations of the mitral apparatus may be responsible for outflow obstruction; the failure to recognize this morphology before operation could have adverse consequences. METHODS AND
RESULTS: We recently evaluated 2 patients with obstructive HCM operated on at Mayo Medical Center in 1997 who demonstrated direct anomalous papillary muscle insertion into the anterior mitral leaflet, producing muscular midcavity obstruction. This anomaly is potentially identifiable with echocardiography by exaggerated anterior displacement of hypertrophied papillary muscles within the left ventricular cavity and the direct continuity between papillary muscle and anterior leaflet associated with a rigid motion pattern of the mitral apparatus. Echocardiographic diagnosis, however, was confused in both patients by the association of systolic anterior motion of the mitral valve, probably produced by freely mobile margins of the mitral leaflet unencumbered by papillary muscle insertion, and in 1 patient probably representing a second and more basal level of obstruction. Because outflow tract morphology was judged unsuitable for conventional myotomy/myectomy, a novel surgical strategy was designed to remove the outflow gradient in which an extensive myectomy trough (wider at its apical than basal extent) was created within the ventricular septum to papillary muscle level; also, in 1 patient, attachment of anterolateral papillary muscle with the lateral free wall was partially severed to increase mobility of the mitral apparatus. After surgery, both patients reported substantial relief of symptoms and improved exercise tolerance and also showed reduced or abolished basal outflow obstruction.
CONCLUSIONS: In HCM, outflow obstruction due to anomalous papillary muscle insertion directly into anterior mitral leaflet is challenging to identify but should always be contemplated before operative intervention. This important (but often unsuspected) congenital malformation may require alternative surgical strategies to standard myotomy/myectomy, similar to those described here.

Entities:  

Mesh:

Year:  1998        PMID: 9843454     DOI: 10.1161/01.cir.98.23.2505

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

2.  Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience.

Authors:  Kunal D Kotkar; Sameh M Said; Joseph A Dearani; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

3.  Mitral valve replacement and septal myectomy for hypertrophic obstructive cardiomyopathy.

Authors:  Kouji Furukawa; Takahiro Hayase; Mitsuhiro Yano
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-04-02

Review 4.  Dual-chamber pacing in hypertrophic cardiomyopathy.

Authors:  D M Gilligan
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

5.  Percutaneous transluminal septal myocardial ablation (PTSMA) for symptomatic patients with hypertrophic obstructive cardiomyopathy: first experience.

Authors:  J M Ten Berg; H H D Idzerda; W Jaarsma
Journal:  Neth Heart J       Date:  2001-11       Impact factor: 2.380

Review 6.  The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice.

Authors:  Iacopo Olivotto; Francesca Girolami; Stefano Nistri; Alessandra Rossi; Luigi Rega; Francesca Garbini; Camilla Grifoni; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-27       Impact factor: 4.132

Review 7.  The diagnosis and treatment of hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Martin Farr; Detlef Hering; Dieter Horstkotte; Lothar Faber
Journal:  Dtsch Arztebl Int       Date:  2011-04-01       Impact factor: 5.594

Review 8.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 9.  Mitral Valve Disease in Hypertrophic Cardiomyopathy:Evaluation and Management.

Authors:  C Charles Jain; Darrell B Newman; Jeffrey B Geske
Journal:  Curr Cardiol Rep       Date:  2019-10-31       Impact factor: 2.931

Review 10.  Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy.

Authors:  Alyson Kelley-Hedgepeth; Martin S Maron
Journal:  Curr Heart Fail Rep       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.